Nonandrogenic Anabolic Hormones Predict Risk of Frailty: European Male Ageing Study Prospective Data
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Context: Low levels of nonandrogenic anabolic hormones have been linked with frailty, but evidence is conflicting and prospective data are largely lacking. Objective: To determine associations between nonandrogenic anabolic hormones and prospective changes in frailty status. Design/Setting: A 4.3-year prospective observational study of community-dwelling men participating in the European Male Ageing Study. Participants: Men (n = 3369) aged 40 to 79 years from eight European centers. Main Outcome Measures: Frailty status was determined using frailty phenotype (FP; n = 2114) and frailty index (FI; n = 2444). Analysis: Regression models assessed relationships between baseline levels of insulinlike growth factor 1 (IGF-1), its binding protein 3 (IGFBP-3), dehydroepiandrosterone sulfate (DHEA-S), 25-hydroxyvitamin D (25OHD), and parathyroid hormone (PTH), with changes in frailty status (worsening or improving frailty). Results: The risk of worsening FP and FI decreased with 1 standard deviation higher IGF-1, IGFBP-3, and 25OHD in models adjusted for age, body mass index, center, and baseline frailty [IGF-1: odds ratio (OR) for worsening FP, 0.82 (0.73, 0.93), percentage change in FI, -3.7% (-6.0, -1.5); IGFBP-3: 0.84 (0.75, 0.95), -4.2% (-6.4, -2.0); 25OHD: 0.84 (0.75, 0.95); -4.4%, (-6.7, -2.0)]. Relationships between IGF-1 and FI were attenuated after adjusting for IGFBP-3. Higher DHEA-S was associated with a lower risk of worsening FP only in men >70 years old [OR, 0.57 (0.35, 0.92)]. PTH was unrelated to change in frailty status. Conclusions: These longitudinal data confirm the associations between nonandrogenic anabolic hormones and the changes in frailty status. Interventional studies are needed to establish causality and determine therapeutic implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Non-androgenic anabolic hormones predict the risk of frailty in aging men, including IGF-I, dehydroepiandrosterone, parathyroid hormone, and 25-OH vitamin D [47].”
From Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review (2019) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Frailty in Older Adults: Evidence for a Phenotype
Fried, L. P., Tangen, C. M., Walston, J., Newman, A. B., Hirsch, C., Gottdiener, J., Seeman, T., Tracy, R., Kop, W. J., Burke, G., et al. (2001) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/56.3.m146 · Cited by 24,907
A standard procedure for creating a frailty index
Searle, S. D., Mitnitski, A., Gahbauer, E. A., Gill, T. M., & Rockwood, K. (2008) · BMC Geriatrics · doi:10.1186/1471-2318-8-24 · Cited by 3,568
The physical activity scale for the elderly (PASE): Development and evaluation
Washburn, R. A., Smith, K. W., Jette, A. M., & Janney, C. A. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90053-4 · Cited by 3,177
Fall risk index for elderly patients based on number of chronic disabilities
Tinetti, M. E., Franklin Williams, T., & Mayewski, R. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90717-5 · Cited by 1,587
Lips, P. (2006) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2006.02.016 · Cited by 1,173
Rajaram, S., Baylink, D. J., & Mohan, S. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0321 · Cited by 1,097
Maninger, N., Wolkowitz, O. M., Reus, V. I., Epel, E. S., & Mellon, S. H. (2009) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2008.11.002 · Cited by 769
An Objective Measure of Physical Function of Elderly Outpatients: The Physical Performance Test
Reuben, D. B., & Siu, A. L. (1990) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1990.tb01373.x · Cited by 728
Research works printed but not linked: 2
- Warrington EK The Camden Memory Tests: Topographical Recognition Memory Test. Hove, United Kingdom: Psychology Press; 1996.
- Uiterwijk JM Wechsler Adult Intelligence Scale III—Nederlandstalige Bewerking (WAIS-III-NL/V). Lisse, Netherlands: Swets & Zeitlinger; 2001.
Cited by
Current and emerging biomarkers of frailty in the elderly
Al Saedi, A., Feehan, J., Phu, S., & Duque, G. (2019) · Clinical Interventions in Aging · doi:10.2147/cia.s168687 · Cited by 178
“Some studies have shown increased levels of PTH to correlate with frailty; 47,48 however, other studies have found that there was no relationship, 49,50 casting doubt on its ability to predict and diagnose frailty.”
Aging and the Male Reproductive System
Kaufman, J.-M., Lapauw, B., Mahmoud, A., T’Sjoen, G., & Huhtaniemi, I. T. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00178 · Cited by 144
Self-citationBauer, J. M., Cruz-Jentoft, A. J., Fielding, R. A., Kanis, J. A., Reginster, J.-Y., Bruyère, O., Cesari, M., Chapurlat, R., Al-Daghri, N., Dennison, E., et al. (2019) · Calcified Tissue International · doi:10.1007/s00223-019-00561-w · Cited by 83
A High Serum Cortisol/DHEA-S Ratio Is a Risk Factor for Sarcopenia in Elderly Diabetic Patients
Yanagita, I., Fujihara, Y., Kitajima, Y., Tajima, M., Honda, M., Kawajiri, T., Eda, T., Yonemura, K., Yamaguchi, N., Asakawa, H., et al. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2018-00271 · Cited by 67
Frailty Status Predicts All-Cause and Cause-Specific Mortality in Community Dwelling Older Adults
Grabovac, I., Haider, S., Mogg, C., Majewska, B., Drgac, D., Oberndorfer, M., & Dorner, T. E. (2019) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.06.007 · Cited by 71
Yanagita, I., Fujihara, Y., Iwaya, C., Kitajima, Y., Tajima, M., Honda, M., Teruya, Y., Asakawa, H., Ito, T., Eda, T., et al. (2020) · BMC Geriatrics · doi:10.1186/s12877-020-01601-z · Cited by 61
Swiecicka, A., Eendebak, R. J. A. H., Lunt, M., O’Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., Giwercman, A., Han, T. S., Slowikowska-Hilczer, J., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01172 · Cited by 45
“We have previously shown that nonandrogenic anabolic hormones such as IGF-1, IGFBP3, and vitamin D were independently associated with change in frailty status in middle-aged and older men (22).”
BackgroundSelf-citationThe operationalization of fatigue in frailty scales: a systematic review
Knoop, V., Costenoble, A., Azzopardi, R. V., Vermeiren, S., Debain, A., Jansen, B., Scafoglieri, A., Bautmans, I., Bautmans, I., Verté, D., et al. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100911 · Cited by 46
Evidence of a Causal Effect of Estradiol on Fracture Risk in Men
Nethander, M., Vandenput, L., Eriksson, A. L., Windahl, S. H., Funck‐Brentano, T., & Ohlsson, C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00934 · Cited by 39
“8 Supplemental Table 1) that may link E2 or T to BMD and/or fracture risk (4, 22-28).”
BackgroundThe endocrinology of sarcopenia and frailty
Kamwa, V., Welch, C., & Hassan-Smith, Z. K. (2022) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03198-3 · Cited by 32
Body Mass Index and Cause-Specific Mortality after Lung Transplantation in the United States
Anderson, M. R., Cantu, E., Shashaty, M. G. S., Benvenuto, L. J., Kalman, L., Palmer, S. M., Singer, J. P., Gallop, R., Diamond, J. M., Hsu, J. Y., et al. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202207-613oc · Cited by 21
Nutritional Considerations in Preventing Muscle Atrophy
Creţoiu, S. M., & Zugravu, C. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1435-3_23 · Cited by 19
Ohlsson, C., Nethander, M., Karlsson, M. K., Rosengren, B. E., Ribom, E. L., Mellström, D., & Vandenput, L. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3418 · Cited by 17
“In prospective analyses, this same study showed that in men over 70years of age, higherDHEAS levels associatedwith a lower riskof worsening frailty.((14)) Intervention studies, however, showed no beneficial effect ofDHEA treatmentonmusclemass((15)) or physical performance outcomes((7,16)) in older men.”
Resultda Silva, J. R. D., Freire, I. V., Ribeiro, Í. J. S., dos Santos, C. S., Casotti, C. A., dos Santos, D. B., Barbosa, A. A. L., & Pereira, R. (2018) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2018.05.008 · Cited by 12
Muscle, endocrine, and immunological markers of frailty in older people
Pillatt, A. P., da Silva, B., Franz, L. B. B., Berlezi, E. M., & Schneider, R. H. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111405 · Cited by 13
Tangwonglert, T., & Davenport, A. (2022) · Nephrology · doi:10.1111/nep.14071 · Cited by 5
Yasui, S., Kaneko, Y., Yamagami, H., Hosoki, M., Hori, T., Tani, A., Hara, T., Kurahashi, K., Harada, T., Nakamura, S., et al. (2023) · Metabolites · doi:10.3390/metabo13111129 · Cited by 3
“Previous studies showed that a high level of DHEAS is associated with a lower risk of worsening frailty in the elderly [6] and that a lower level of DHEAS may indicate a poorer prognosis in patients with atherosclerosis [7] and cardiovascular diseases [8].”
ResultThe Effect of Concurrent Training on Serum Androgens Levels and Sexual Function in Menopausal Women
Parastesh, M., Mohseni, Z., Zadeh, E. K., & Saremi, A. (2021) · Avicenna Journal of Nursing and Midwifery Care · doi:10.30699/ajnmc.29.4.292 · Cited by 1
Gluchowski, A. (2018) · Tuwhera (Auckland University of Technology)
Modern use of biomarkers in geriatric medicine
Walter, S. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch109
Handgrip Strength and Dehydroepiandrosterone Sulfate in a Frailty Unit: A Retrospective Study
Caires, D., Costa, M. H., Freitas, J. M., Nascimento, R. F., Teófilo, T. J. S., dos Santos, L. R., Gouveia, J., & Carvalhinha, C. (2024) · Cureus · doi:10.7759/cureus.69753
“The decline in DHEAS levels has often been implicated in age-related physiological changes, comprising overall muscle strength reduction and decreased physical activity as well as the development of various age-related conditions, including frailty [12,14-18].”
BackgroundAntunes, J. M. M., Ferreira, R. M., Santos, L. L., & Moreira‐Gonçalves, D. (2026) · GeroScience · doi:10.1007/s11357-026-02302-y
Frailty in Older Adults: Pathogenesis, Treatment and Prevention
Lema‐Arranz, C., Fernández‐Bertólez, N., Lorenzo‐López, L., Valdiglesias, V., & Laffón, B. (2026) · Current Epidemiology Reports · doi:10.1007/s40471-026-00406-9 · Cited by 1
“All these changes in anabolic hormones are considered important contributors to the development of frailty [74 ] and numerous studies showed associations of lower levels of these hormones with a multisystem state of senescence and frailty [reviewed in 21 ].”
Metadata
- Authors
- Swiecicka, A., Lunt, M., Ahern, T., O’Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., Giwercman, A., Han, T. S., Lean, M. E. J., Pendleton, N., Punab, M., Slowikowska-Hilczer, J., Vanderschueren, D., Huhtaniemi, I. T., Wu, F. C. W., Rutter, M. K., & for the EMAS Study Group
- Affiliations
- Andrology Research Unit, Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9WL, United Kingdom
- Manchester Academic Health Science Centre (GB)
- Department of Obstetrics, Gynecology and Andrology, Albert Szent-György Medical University, H6725 Szeged, Hungary
- Complejo Hospitalario Universitario de Santiago (ES)
- University of Florence (IT)
- Lund University (SE)
- Royal Holloway University of London (GB)
- University of Glasgow (GB)
- University of Manchester (GB)
- Tartu University Hospital (EE)
- Department of Andrology and Reproductive Endocrinology, Medical University of Lodz, 90-419 Lodz, Poland
- KU Leuven (BE)
- University of Turku (FI)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2017-05-09
- Volume
- 102
- Issue
- 8
- Pages
- 2798-2806
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC5546856
- OpenAlex
- W2612314571
- Cited by
- 23
- References
- 38
- Citations by year
- 2026: 2 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 6 · 2018: 5 · 2017: 1
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Lirias (submittedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- GlaxoSmithKline
- National Institute for Health and Care Research
- Novo Nordisk
- Versus Arthritis
- Mereo BioPharma
- Manchester Biomedical Research Centre
- Medical Research Council (MR/K025252/1)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Geriatrics and Gerontology › Frailty in Older Adults
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Keywords
- frailty, insulin-like growth factor I, IGFBP-3, dehydroepiandrosterone sulfate, 25-hydroxyvitamin D, parathyroid hormone, frailty index, Fried frailty phenotype, men, aging, community-dwelling older men, vitamin D, sex steroids
- MeSH terms
- Adult, Aged, Aging, Humans, Insulin-Like Growth Factor I, Longitudinal Studies, Male, Middle Aged, Parathyroid Hormone, Prospective Studies, Vitamin D, Odds Ratio, Frail Elderly, Risk Assessment, Insulin-Like Growth Factor Binding Protein 3, Dehydroepiandrosterone Sulfate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.